Hangzhou, Zhejiang, China In 2011 was created Haibang Capital, which is appeared as VC. The main department of described VC is located in the Hangzhou. The company was established in Asia in China.
Among the most successful fund investment fields, there are Medical, Psychology. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Zylox, Zylox, IMPACT Therapeutics For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Haibang Capital, startups are often financed by Yueyin Venture Capital, WuXi Healthcare Ventures, Proxima Ventures Ltd. The meaningful sponsors for the fund in investment in the same round are Juren Capital, Highlight Capital, Yueyin Venture Capital. In the next rounds fund is usually obtained by SDIC Fund Management, Lilly Asia Ventures, Juren Capital.
The usual things for fund are deals in the range of 5 - 10 millions dollars. The important activity for fund was in 2015. The fund is constantly included in less than 2 investment rounds annually. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations.
The current fund was established by Gang Liang, Li Xie, Naxin Yao.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Connor Capital SB | - |
| iQiyi Sports | Beijing, Beijing, China |
| IT Co | - |
| Jipyong | Seoul, Seoul-t'ukpyolsi, South Korea |
| Madison Capital Partners | Chicago, Illinois, United States |
| Novartis | Basel, Basel-Stadt, Switzerland |
| Oikocredit International | Amersfoort, The Netherlands, Utrecht |
| Pine Street Capital Partners | Massachusetts, United States, Wellesley |
| TOS TV OITA | Japan, Tokyo |
| Zhangke Lingyi Investment | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
LYNK Pharmaceuticals | $18M | 21 Sep 2023 | Hangzhou, Zhejiang, China | ||
Zhongzhiwei Technology | $15M | 01 Aug 2023 | Jiangsu, Guangxi, China | ||
Jinmate | $30M | 19 Apr 2023 | Huzhou, Zhejiang, China | ||
Healsun Biopharm | $38M | 19 Aug 2022 | Hangzhou, Zhejiang, China | ||
Hengyu Biotechnology | 25 Jul 2022 | Jiaxing, Zhejiang, China | |||
DECANS | $77M | 21 Feb 2022 | Jiaxing, Zhejiang, China | ||
Jiu Zong | 12 Nov 2021 | Ningbo, Zhejiang, China | |||
Odianyun | $15M | 01 Nov 2021 | Shanghai, Shanghai, China | ||
T-Maximum | 20 Aug 2021 | Suzhou, Jiangsu, China |
– Sciwind biosciences secured US$37m series B financing.
– The financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.
– Sciwind focuses on research and development of innovative biologics in the therapeutic area of chronic metabolic and immunological diseases and has driven multiple projects into clinical trials.
– Two more IND applications are expected to be filed in 2021 including an oral formulation of a highly active GLP-1 analogue.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
LYNK Pharmaceuticals | $18M | 21 Sep 2023 | Hangzhou, Zhejiang, China | ||
Zhongzhiwei Technology | $15M | 01 Aug 2023 | Jiangsu, Guangxi, China | ||
Jinmate | $30M | 19 Apr 2023 | Huzhou, Zhejiang, China | ||
Healsun Biopharm | $38M | 19 Aug 2022 | Hangzhou, Zhejiang, China | ||
Hengyu Biotechnology | 25 Jul 2022 | Jiaxing, Zhejiang, China | |||
DECANS | $77M | 21 Feb 2022 | Jiaxing, Zhejiang, China | ||
Jiu Zong | 12 Nov 2021 | Ningbo, Zhejiang, China | |||
Odianyun | $15M | 01 Nov 2021 | Shanghai, Shanghai, China | ||
T-Maximum | 20 Aug 2021 | Suzhou, Jiangsu, China |
